Diversified Trust Co Purchases Shares of 1,972 Moderna, Inc. (NASDAQ:MRNA)


Share on StockTwits

Diversified Trust Co purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, HoldingsChannel reports. The firm purchased 1,972 shares of the company’s stock, valued at approximately $206,000.

Several other institutional investors and hedge funds also recently made changes to their positions in MRNA. American International Group Inc. increased its position in shares of Moderna by 49.0% during the second quarter. American International Group Inc. now owns 7,350 shares of the company’s stock valued at $472,000 after acquiring an additional 2,418 shares during the last quarter. FMR LLC increased its position in shares of Moderna by 51.6% during the second quarter. FMR LLC now owns 37,532,143 shares of the company’s stock valued at $2,409,938,000 after acquiring an additional 12,772,752 shares during the last quarter. Stifel Financial Corp boosted its stake in shares of Moderna by 75.7% in the second quarter. Stifel Financial Corp now owns 20,547 shares of the company’s stock valued at $1,319,000 after purchasing an additional 8,853 shares during the period. Private Advisor Group LLC boosted its stake in shares of Moderna by 113.0% in the second quarter. Private Advisor Group LLC now owns 20,035 shares of the company’s stock valued at $1,286,000 after purchasing an additional 10,631 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its stake in shares of Moderna by 19.6% in the second quarter. Public Employees Retirement System of Ohio now owns 102,491 shares of the company’s stock valued at $6,581,000 after purchasing an additional 16,812 shares during the period. Institutional investors and hedge funds own 53.06% of the company’s stock.

Shares of NASDAQ:MRNA opened at $124.06 on Thursday. The company has a market capitalization of $49.09 billion, a PE ratio of -76.58 and a beta of 1.84. The company has a current ratio of 2.43, a quick ratio of 2.43 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a twelve month low of $17.91 and a twelve month high of $178.50. The firm has a 50 day simple moving average of $131.20 and a 200-day simple moving average of $86.79.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.16). The company had revenue of $157.90 million for the quarter, compared to analysts’ expectations of $82.50 million. Moderna had a negative return on equity of 28.11% and a negative net margin of 242.73%. The firm’s quarterly revenue was up 828.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.37) EPS. As a group, equities research analysts predict that Moderna, Inc. will post -1.77 EPS for the current fiscal year.

Several research analysts have recently commented on MRNA shares. The Goldman Sachs Group reissued a “buy” rating and issued a $139.00 price objective on shares of Moderna in a research note on Friday, December 11th. Jefferies Financial Group lowered shares of Moderna from a “buy” rating to a “hold” rating and raised their price objective for the company from $90.00 to $150.00 in a research note on Tuesday, December 15th. Bank of America lifted their price target on shares of Moderna from $105.00 to $150.00 in a research note on Thursday, December 3rd. Morgan Stanley downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $100.00 to $150.00 in a research note on Wednesday, December 16th. Finally, Needham & Company LLC downgraded shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 9th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $130.67.

In other Moderna news, insider Juan Andres sold 5,000 shares of the business’s stock in a transaction on Monday, January 11th. The shares were sold at an average price of $112.83, for a total value of $564,150.00. Following the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at approximately $564,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephane Bancel sold 11,046 shares of the business’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $68.36, for a total transaction of $755,104.56. Following the completion of the transaction, the chief executive officer now directly owns 6,603,868 shares in the company, valued at $451,440,416.48. The disclosure for this sale can be found here. Insiders sold a total of 490,122 shares of company stock worth $53,843,641 over the last ninety days. Corporate insiders own 29.20% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Read More: Penny Stocks

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.